ClinicalTrials.gg
CompletedNCT04432324Updated Mar 10, 2021

Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)

A Phase 2 interventional study of Intravenous Immune Globulin and Standard Medical Treatment in COVID-19, sponsored by Instituto Grifols, S.A.. Completed at 10 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-10.

Sponsored by Instituto Grifols, S.A. (part of Grifols) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 401 studies in COVID-19 with a site in Spain — 25 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · Spain.

Enrollment
146th of 254
100 · median 132
Started
2020
with 204 others
Phase 2
54 of 401
1 open now
Registered
111th of 401
by date

Among the 401 studies in COVID-19 with a site in Spain, this one is the 146th largest by enrollment of the 254 interventional ones that give a count, is one of 205 that started in 2020, is one of 54 in phase 2, and was the 111th registered.

COVID-19

7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

25 of the 401 studies in COVID-19 with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in COVID-19 with a site in Spain, or all of them as a file.
02

Study summary

The purpose of the study is to determine if high dose Intravenous IVIG plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day 29 or who are dependent on high flow oxygen devices or invasive mechanical ventilation on Day 29 versus SMT alone in hospitalized participants with COVID-19.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • Coronavirus Disease
  • Severe acute respiratory syndrome coronavirus 2
  • SARS-CoV-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hospitalized male or female subject ≥ 18 years of age at time of Screening who is being treated for COVID-19.
  2. Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by qualitative Polymerase Chain Reaction (PCR) (reverse transcriptase [RT]-PCR), or other commercial or public health assay (of any type) in any specimen during the current hospital admission prior to randomization.
  3. COVID-19 illness (symptoms) of any duration with radiographic infiltrates by imaging (Chest X-Ray, Computed tomography (CT) scan, etc.).
  4. PaO2/FIO2 ratio > 300 to ≤ 450 mmHg (i.e., arterial oxygen in mmHg divided by fraction inspired oxygen concentration [e.g., 0.21 for room air])
  5. Any one of the following related to COVID-19: i. Ferritin > 400 nanogram per milliliter (ng/mL), ii. Lactate dehydrogenase (LDH) > 300 units per liter U/L, iii. D-Dimers > reference range, or iv. C-reactive protein (CRP) > 40 milligram per liter (mg/L).
  6. Subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides oral prior to initiation of any study procedures.

Exclusion criteria

Exclusion criteria:

  1. Subject requires invasive mechanical ventilation or ICU admission.
  2. Clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator may place the subject at undue medical risk.
  3. The subject has had a known (documented) serious anaphylactic reaction to blood, any blood-derived or plasma product or commercial immunoglobulin.
  4. Subject has known (documented) hereditary fructose intolerance (HFI).
  5. A medical condition in which the infusion of additional fluid is .
  6. Shock that is unresponsive to fluid challenge and/or multiple vasopressors and accompanied by multiorgan failure considered by the Principal Investigator not able to be reversed.
  7. Subject with known (documented) thrombotic complications to polyclonal IVIG therapy in the past.
  8. Subject with current or prior (within the past 1 month) myocardial infarction, stroke, deep vein thrombosis, or thromboembolic event.
  9. Subject with limitations of therapeutic effort (eg, 'do not resuscitate' status).
  10. Female subject who are pregnant or of with a positive test for pregnancy blood or urine human chorionic gonadotropin (HCG)-based assay at Screening/Baseline.
  11. Subject participating in another interventional clinical trial with medical product or device.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Intravenous Immune Globulin + Standard Medical Treatment

    Participants will receive the first intravenous (IV) infusion of IVIG on Day 1 up to a net dose of 2 gram per kilogram (g/kg), based upon participant's (body weight) administered in divided doses as infusions of 500 milligram per kilogram (mg/kg), based upon participant's body weight, over 4 days or 400 mg/kg, based upon participant's body weight, over 5 days. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.

    Biological: Intravenous Immune Globulin · Drug: Standard Medical Treatment

  • Active comparator
    Standard Medical Treatment

    Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29

    Drug: Standard Medical Treatment

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Dying or Requiring ICU Admission

    Time frame: Up to Day 29

  2. Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation

    Time frame: Day 29

Secondary outcomes

  1. Change from Baseline in National Early Warning Score (NEWS)

    Time frame: Day 1 through Day 29

  2. Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours

    Time frame: Day 1 through Day 29

  3. Time to Hospital Discharge

    Time frame: Day 1 through Day 29

  4. Duration of ICU Stay

    Time frame: Up to Day 29

  5. Duration of Any Oxygen Use

    Time frame: Day 1 through Day 29

  6. Duration of Mechanical Ventilation

    Time frame: Up to Day 29

  7. Mean Change from Baseline in Ordinal Scale

    Time frame: Day 1 through Day 29

  8. Absolute Value Change from Baseline in Ordinal Scale

    Time frame: Day 1 through Day 29

  9. Length of Time to Clinical Progression

    Time frame: Up to Day 29

  10. Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale

    Time frame: Day 15 and Day 29

  11. Time to Sustained Normalization of Temperature

    Time frame: Day 1 through Day 29

  12. Percentage of Participants with Normalization of Fever

    Time frame: Day 1 through Day 29

  13. Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)

    Time frame: Day 29

07

Study locations

10 sites
  • Hospital Universitario Infanta Sofía
    San Sebastián De Los Reyes, Madrid 28702, Spain
  • Hospital Germans Trias i Pujol
    Badalona, 08916, Spain
  • Hospital Del Mar
    Barcelona, 08003, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, 08907, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, CP 08041, Spain
  • Hospital Universitario de Getafe
    Getafe, 28905, Spain
  • Hospital Arnau de Vilanova
    Lleida, 25198, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Mar 2021, 9 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 9 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2020
First posted
Jun 16, 2020
StartActual
Jun 2, 2020
Primary completionActual
Mar 3, 2021
CompletionActual
Mar 3, 2021
Last update
Mar 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04432324
Responsible party
Sponsor
First posted
Jun 16, 2020
Start date
Jun 2, 2020
Primary completion
Mar 3, 2021
Completion
Mar 3, 2021
Last update
Mar 10, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion